Following addition of a TF blocking antibody, the lag phase did not change in pancreatic cancer patients and healthy controls, Vmax decreased significantly in pancreatic cancer patients but not in controls, ΔAbs decreased significantly in pancreatic cancer patients and in healthy controls, and time to peak fibrin generation was reduced in pancreatic cancer patients with borderline significance, but not in controls (Figure 2). Here, TF is linked to pancreatic neoplasm.